NCT03677466 (HaemInCor) is a NA clinical trial of Pharmaco-invasive strategy in Myocardial Infarction, sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences.

Who is sponsoring NCT03677466?

NCT03677466 is sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences.

What drugs are being tested in NCT03677466?

Interventions in NCT03677466: Pharmaco-invasive strategy, Primary PCI.

What condition does NCT03677466 study?

NCT03677466 studies Myocardial Infarction, STEMI, Myocardial Necrosis, Myocardial Injury.

Is NCT03677466 still recruiting?

NCT03677466 is currently completed. Last updated 5 April 2019.

Last reviewed 2019-04-05 · How we verify

NCT03677466: HaemInCor

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intramyocardial Haemorrhage in Patients With Primary STEMI

Completed NA Last updated 5 April 2019

What this trial tests

NA trial testing Pharmaco-invasive strategy in Myocardial Infarction in 60 participants. Completed in 20 March 2019.

Timeline

25 January 2018

Primary endpoint
30 October 2018

20 March 2019

Quick facts

Lead sponsor	Tomsk National Research Medical Center of the Russian Academy of Sciences
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	60
Start date	25 January 2018
Primary completion	30 October 2018
Estimated completion	20 March 2019
Sites	1 location across Russia

Drugs / interventions tested

Pharmaco-invasive strategy — full drug profile →
Primary PCI

Conditions studied

Myocardial Infarction — all drugs for Myocardial Infarction →
STEMI — all drugs for STEMI →
Myocardial Necrosis — all drugs for Myocardial Necrosis →
Myocardial Injury — all drugs for Myocardial Injury →

Sponsor

Tomsk National Research Medical Center of the Russian Academy of Sciences

Who can join

18 and older, any sex, with Myocardial Infarction or STEMI. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to assess the frequency and intensity of intramyocardial haemorrhage in patients with primary STEMI and different reperfusion strategies.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Abstracts of the Heart Failure 2019 and the World Congress on Acute Heart Failure, 25-28 May 2019, Megaron Athens International Conference Centre, Greece.
· 2019 · cited 5× · PMID 32745277 · DOI 10.1002/ejhf.1488

Verify or expand the search:

Other recruiting trials for Myocardial Infarction

Currently open trials in the same condition.

NCT07257198 — Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone · Phase 3 · recruiting
NCT07402642 — Effect of Early Educational Intervention on Cardiovascular Risk Factors After Acute Coronary Syndrome · NA · recruiting
NCT07301034 — A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, · Phase 3 · recruiting
NCT07142265 — Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients · recruiting
NCT07138911 — Effect of Home-based Exercise Plan Mediated by Use of Digital Health App on Kinesiophobia and Functional Capacity · NA · recruiting

Other Tomsk National Research Medical Center of the Russian Academy of Sciences trials

Trials by the same sponsor.

NCT07457541 — Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI · Phase 1 · active not recruiting
NCT07475390 — 99mTc-1-thio-D-glucose SPECT/CT Versus 18F-Fluoroethyl-l-tyrosine PET/CT in Brain Tumor Imaging · NA · active not recruiting
NCT07292571 — Evaluation of Different Types of HER2 Expression in Breast Cancer Using [99mTc]Tc -ZHER2:4107 · Phase 2 · enrolling by invitation
NCT07275463 — [99mTc]Tc-DB8 Accumulation in Primary Tumor in Breast Cancer With Positive and Negative Estrogen Receptor Expression · Phase 2 · enrolling by invitation
NCT07018895 — Personalized Hypoxic-hyperoxic Preconditioning in Elderly People · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03677466 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tomsk National Research Medical Center of the Russian Academy of Sciences
Last refreshed: 5 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03677466.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing